Literature DB >> 20944171

Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas.

Toshihiro Fukushima1, Takuji Nakamura, Miyuki Miki, Tomoyuki Sakai, Haruka Iwao, Akio Nakajima, Toshioki Sawaki, Yoshimasa Fujita, Masao Tanaka, Yasufumi Masaki, Yuko Hirose, Hisanori Umehara.   

Abstract

BACKGROUND: A case of relapsed multiple myeloma (MM) with multiple plasmacytomas of the parietal bone and the right orbit in which was achieved a complete response with bortezomib plus dexamethasone (BD) therapy is reported. A Japanese woman with Bench-Jones lambda-type MM who achieved a plateau phase with nine courses of melphalan plus prednisolone therapy complained of right exophthalmos and numbness around her mouth. Computed tomographic (CT) scan and T2-weighted magnetic resonance imaging showed tumours at the parietal bone and the right orbit. A tumour biopsy from the parietal bone revealed the histological morphology of a plasmacytoma. She was therefore diagnosed with relapsed MM with multiple plasmacytomas, and received BD therapy. A CT scan after the end of the second course of treatment revealed the disappearance of the plasmacytomas. At the end of the fifth course, no lambda light chain was detected by immunofixation of serum and urine, and the pathological plasma cells in bone marrow were fewer than 5%; therefore, she had achieved a complete response. The time to disease progression from the first course of BD therapy and the treatment-free interval were 400 days and 134 days, respectively.
CONCLUSION: This case report indicates that bortezomib may be a promising agent for MM with multiple plasmacytomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20944171

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Plasmacytoma presenting as hematuria.

Authors:  Khurram Abbass; Shabana Dewani; Ronald Markert; Michael K Kaplon; Michael A Baumann
Journal:  Int J Hematol       Date:  2011-05-07       Impact factor: 2.490

2.  A Case of Disseminated and Fulminant Plasmacytomas That Developed during Bortezomib Treatment.

Authors:  Soo-Young Bae; Jae-Sook Ahn; Deok-Hwan Yang; Yeo-Kyeoung Kim; Jung-Joon Min; Ho-Chun Song; Hee-Seung Bom; Yong Yeon Jeong; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Case Rep Oncol       Date:  2011-02-25

3.  Cutaneous Vasculitis: An Unusual Presentation of a Biclonal Nodal Plasma Cell Dyscrasia.

Authors:  D Swan; M Murphy; E Elhassadi
Journal:  Case Rep Hematol       Date:  2017-09-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.